AZD-7325

Generic Name: AZD-7325

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₉FN_₄O_₂

CAS Number: 942437-37-8

Unique Ingredient Identifier: KNM216XOUH

Background: AZD7325 is a high affinity, selective modulator of the GABAA receptor system.

Clinical Trials

Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial

Phase 2

Completed

Conditions: Autism Spectrum Disorder

Interventions: Drug: AZD7325
Drug: Placebo

First Posted Date: 2013-10-21

Last Posted Date: 2015-10-22

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 40

Registration Number: NCT01966679

Locations: 🇺🇸
Seattle Children's Research Institute, Seattle, Washington, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

AZD7325 Japan Multiple Ascending Dose (MAD) Study

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: AZD7325
Drug: Placebo

First Posted Date: 2009-07-24

Last Posted Date: 2011-02-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 48

Registration Number: NCT00945425

Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration

Phase 1

Suspended

Conditions: Absorption
Distribution
Metabolism
Excretion

Interventions: Drug: AZD7325

First Posted Date: 2009-07-16

Last Posted Date: 2011-01-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 8

Registration Number: NCT00940641

Locations: 🇬🇧
Research Site, Alderley Park, United Kingdom

Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users

Phase 1

Completed

Conditions: Recreational CNS Depressant Use

Interventions: Drug: AZD7325
Drug: Placebo
Drug: Lorazepam

First Posted Date: 2009-05-15

Last Posted Date: 2009-09-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 100

Registration Number: NCT00902772

Locations: 🇨🇦
Research Site, Toronto, Ontario, Canada

Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects

Phase 1

Suspended

Conditions: Pharmacokinetics

Interventions: Drug: monophasic oral contraceptive
Drug: AZD7325

First Posted Date: 2009-05-13

Last Posted Date: 2010-12-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 56

Registration Number: NCT00901290

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

Phase 2

Completed

Conditions: Anxiety Disorders

Interventions: Drug: AZD7325
Drug: Placebo

First Posted Date: 2008-12-15

Last Posted Date: 2011-06-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 725

Registration Number: NCT00808249

Locations: 🇺🇸
Research Site, Middleton, Wisconsin, United States

Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

Phase 2

Completed

Conditions: Anxiety Disorders

Interventions: Drug: AZD7325
Drug: Lorazepam
Drug: Placebo

First Posted Date: 2008-12-15

Last Posted Date: 2010-10-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 369

Registration Number: NCT00807937

Locations: 🇺🇸
Research Site, Seattle, Washington, United States

Determine the Effect of Multiple Doses of AZD7325, CYP Study

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: AZD7325
Drug: Midazolam
Drug: Caffeine

First Posted Date: 2008-11-13

Last Posted Date: 2008-11-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT00790114

AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: AZD7325

First Posted Date: 2008-10-09

Last Posted Date: 2009-03-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 48

Registration Number: NCT00769899

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator.

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: AZD7325
Drug: Lorazepam

First Posted Date: 2008-07-22

Last Posted Date: 2010-12-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 16

Registration Number: NCT00720421

Locations: 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy